The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IWWM-12 2024 | The evolving role of genomics in the treatment of WM: MYD88, CXCR4, and TP53
Steven Treon, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses the evolving role of genomics in the treatment of Waldenström’s macroglobulinemia (WM), highlighting the significance of the MYD88, CXCR4, and TP53 mutations. He mentions the potential of targeted therapies dependent on the mutational status of individual patients. This interview took place at the 12th International Workshop on Waldenström’s Macroglobulinemia (IWWM-12) in Prague, Czech Republic.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
